EBI-907

antineoplastic; structure in first source

Networked: 2 relevant articles (1 outcomes, 1 trials/studies)

1.	Neoplasms (Cancer) 01/01/2016 - "Our chemistry effort has led to the discovery of EBI-907 as a novel BRAF(V600E) inhibitor with potent anti-tumor activity in vitro and in vivo. " 02/01/2016 - "One of the compounds EBI-907 (13g) demonstrated excellent in vivo efficacy in B-Raf(V600E) dependent Colo-205 tumor xenograft models in mouse and is under preclinical studies for the treatment of melanoma and B-Raf(V600E) associated cancers. " 01/01/2016 - "In BRAF(V600E)-dependent human Colo-205 and A375 tumor xenograft mouse models, EBI-907 caused a marked tumor regression in a dose-dependent manner, with superior efficacy to Vemurafenib. " 01/01/2016 - "EBI-907, a novel BRAF(V600E) inhibitor, has potent oral anti-tumor activity and a broad kinase selectivity profile."
2.	Melanoma (Melanoma, Malignant) 02/01/2016 - "One of the compounds EBI-907 (13g) demonstrated excellent in vivo efficacy in B-Raf(V600E) dependent Colo-205 tumor xenograft models in mouse and is under preclinical studies for the treatment of melanoma and B-Raf(V600E) associated cancers. "
3.	Colorectal Neoplasms (Colorectal Cancer) 01/01/2016 - "Concomitant with such properties, EBI-907 exhibits potent and selective cytotoxicity against a broader range of BRAF(V600E)-dependent cell lines including certain colorectal cancer cell lines with innate resistance to Vemurafenib. "

1.	Vemurafenib
2.	Phosphotransferases (Kinase)